Neumora Therapeutics, Inc. (NMRA) · Oct 30, 2026 · Delisting
Bid-price deficiency — $1.00 minimum bid; 180 days to April 26, 2027
Neumora’s delisting notice gives the biotech 180 days to regain Nasdaq’s $1 minimum bid price, adding a capital-markets problem to its pipeline rebuild.
Neumora is a clinical-stage biotech rebuilding around newer programs including NMRA-511, NMRA-898, and NMRA-215 after its late-stage navacaprant depression studies failed; management’s latest plan still pointed to clinical data and new program advancement in late 2026. This filing does not change that pipeline, but it adds a new exchange-compliance problem to the story.
The listing is now formally at risk, not immediately lost. Nasdaq says Neumora is below the $1.00 minimum bid requirement, giving it until April 26, 2027 to post a closing bid of at least $1.00 for ten consecutive business days.
The likely remedy could create a corporate-action overhang. Neumora says it is considering options including a reverse stock split, while a failure to cure the deficiency could lead to delisting proceedings and a possible appeal. 〔0〕 A reverse split would mechanically raise the quoted share price but would not improve the underlying pipeline, financing capacity, or clinical evidence.
This is partly known but still negative new information. A prolonged sub-$1 share price made a deficiency notice foreseeable, so the filing is not a surprise about the company’s operating science. But the formal deadline and explicit reverse-split consideration convert that weakness into a defined capital-markets issue while investors await the next clinical milestones.
Bottom line: Neumora has time to cure the Nasdaq deficiency, but the filing adds avoidable listing and reverse-split risk to an already high-stakes pipeline rebuild. It matters more for the company’s financing and market-access mechanics than for its drug programs themselves.
Regain $1 bid price by April 26, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!